Vistagen Therapeutics Files 8-K
Ticker: VTGN · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K on Jan 10th, check for updates.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting an event that occurred on January 10, 2025. The filing pertains to 'Other Events' and 'Financial Statements and Exhibits'. The company is incorporated in Nevada and headquartered in South San Francisco, California.
Why It Matters
This 8-K filing indicates a material event or change for Vistagen Therapeutics, Inc., requiring disclosure to investors.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for 'Other Events' and does not appear to disclose immediate negative financial or operational news.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- January 10, 2025 (date) — Date of earliest event reported
- January 13, 2025 (date) — Date of Report
- Nevada (jurisdiction) — State of incorporation
- South San Francisco, California (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Vistagen Therapeutics, Inc. in this 8-K?
The provided text does not detail the specific 'Other Events' beyond listing the item category.
What is the significance of filing 'Financial Statements and Exhibits' in this 8-K?
This indicates that financial information or exhibits related to the reported event are being provided as part of the filing.
When was Vistagen Therapeutics, Inc. incorporated?
Vistagen Therapeutics, Inc. was incorporated in Nevada.
What is the business address and phone number for Vistagen Therapeutics, Inc.?
The business address is 343 Allerton Ave., South San Francisco, California, 94080, and the phone number is (650) 577-3600.
Has Vistagen Therapeutics, Inc. had previous names?
Yes, the company was formerly known as VistaGen Therapeutics, Inc. (name change on 20110610) and Excaliber Enterprises, Ltd. (name change on 20070906).
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-13 17:28:45
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn-20250110.htm (8-K) — 24KB
- vtgnfasrdsinitiationpr2025.htm (EX-99.1) — 14KB
- image.jpg (GRAPHIC) — 10KB
- 0001411685-25-000004.txt ( ) — 176KB
- vtgn-20250110.xsd (EX-101.SCH) — 2KB
- vtgn-20250110_lab.xml (EX-101.LAB) — 21KB
- vtgn-20250110_pre.xml (EX-101.PRE) — 12KB
- vtgn-20250110_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On January 10, 2025, Vistagen Therapeutics, Inc. (the " Company ") issued a press release to announce that it has enrolled the first subject in an exploratory repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray, as part of its fasedienol U.S. Phase 3 development program for the acute treatment of social anxiety disorder. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated January 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: January 13, 2025 By: /s/ Shawn K. Singh Shawn K. Singh Chief Executive Officer